Dynavax Technologies | DVAX - Stock


Dynavax Technologies reported $73.29M in Stock for its fiscal quarter ending in September of 2025.



Stock Change Date
AbbVie USD 5.05B 98M Mar/2026
Adma Biologics USD 222.1M 15.63M Mar/2026
Amgen USD 6.19B 39M Mar/2026
AstraZeneca USD 6.57B 13M Mar/2026
Biogen USD 1.95B 219.1M Mar/2026
BioMarin Pharmaceutical USD 1.27B 25.66M Mar/2026
Bristol-Myers Squibb USD 2.76B 66M Mar/2026
Gilead Sciences USD 1.91B 140M Mar/2026
Glaxosmithkline GBP 6.12B 46M Sep/2025
Merck USD 6.48B 179M Mar/2026
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Neurocrine Biosciences USD 64.5M 4.5M Mar/2026
Novartis USD 6.29B 17M Mar/2026
Pfizer USD 10.67B 13M Mar/2026
Regeneron Pharmaceuticals USD 3.1B 97.2M Mar/2026
Roche Holding CHF 7.6B 9M Jun/2025
Sarepta Therapeutics USD 1B 86.37M Mar/2026
TG Therapeutics USD 129.03M 3.44M Mar/2026
Vertex Pharmaceuticals USD 1.77B 79.9M Mar/2026